SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark Phase 3 cardiovascular outcomes trial enrolling 17,604 adults with preexisting cardiovascular disease and obesity or overweight, but WITHOUT diabetes
As a triple agonist activating GLP-1, GIP, and glucagon receptors, it provides the most comprehensive receptor coverage available
Youve made real progress with semaglutide, your clothes fit better, the scale has been moving, and for the first time in a long time, you feel in control of your weight loss journey
We recommend reaching out to your provider to discuss your options and determine the best course of action for your health
Go to FreedomDiagnosticsTesting.com and search accession number 2603130113 or search code Prof2603130113